Merck Invests $6M in Remedy Informatics to Support Healthcare IT Development | GenomeWeb

Remedy Informatics said this week that the Merck Global Health Innovation Fund, the investment arm of pharmaceutical giant Merck, has invested about $6 million in growth capital in the company.

The investment gives Merck a seat on Remedy’s board of directors and the opportunity for additional investments in the future, Remedy said.

The capital from Merck “will fuel our growth here in the US and our expansion into Europe and Latin America," Gary Kennedy, Remedy’s founder and CEO, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.